Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic diseases and cancer by targeting galectin proteins. Its lead candidate, belapectin (GR-MD-02), is a carbohydrate-based galectin-3 inhibitor. The company has no commercial products and has incurred net losses since its inception in 2000.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(30.8) million | $(47.0) million |
| Operating Expenses | $(20.1) million | $(42.4) million |
| Research & Development (R&D) | $(14.3) million | $(36.6) million |
| General & Administrative (G&A) | $(5.8) million | $(5.9) million |
| Cash and Cash Equivalents (End of Period) | $17.7 million | $15.1 million |
| Net Cash Used in Operating Activities | $(23.9) million | $(41.8) million |
| Accumulated Deficit | $(432.5) million | $(401.6) million |
| Convertible Debt & Line of Credit (Related Party) | ~$133.7 million (Total Liabilities) | ~$106.2 million (Total Liabilities) |
Note: Total liabilities include convertible notes, derivative liabilities, and borrowings under a related-party line of credit. The company has no revenue.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 53% from $42.4 million in 2024 to $20.1 million in 2025. This was primarily driven by a 61% reduction in R&D expenses ($36.6M to $14.3M) as the company wound down costs associated with the NAVIGATE clinical trial.
- Net Loss Improvement: Net loss narrowed by 34% to $30.8 million, reflecting lower operating costs, partially offset by a significant non-cash loss from the change in fair value of derivative liabilities ($3.5 million loss in 2025 vs. $0.6 million gain in 2024).
- Financing Activity: The company raised $21.0 million in proceeds from a convertible line of credit provided by its Chairman in 2025, compared to $30.0 million in 2024. Additionally, the company extended the maturity dates of existing convertible notes and lines of credit to June 30, 2027.
Guidance, Outlook, and Risks
Clinical Trial Results (NAVIGATE)
The company presented top-line results for the NAVIGATE Phase 2b/3 trial in December 2024. While the primary composite endpoint did not reach statistical significance in the Intent-to-Treat (ITT) population, the Per-Protocol Population (PPP) showed a 49.3% reduction in the incidence of esophageal varices (p < 0.05). A U.S. subgroup analysis showed a 68.1% reduction (p=0.02). The company plans to pursue a Type C meeting with the FDA to finalize the design for a potential pivotal Phase 3 trial, though no Phase 3 trial is currently funded or guaranteed.
Liquidity and Capital Resources
As of December 31, 2025, the company held $17.7 million in unrestricted cash and had $10 million available under a line of credit from its Chairman. Management believes these resources are sufficient to fund operations through April 2027. The company will require additional capital thereafter and faces risks related to its ability to secure financing on favorable terms.
Key Risks
- Going Concern: The company has a history of net losses and no revenue. Continued operations depend on raising additional capital.
- Dependence on Key Individual: The company is significantly dependent on Chairman Richard E. Uihlein for financing. There is no assurance he will continue to provide funding.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to the valuation of derivative liabilities associated with contingent interest on convertible notes.
- Regulatory Uncertainty: Future clinical trials and regulatory approval are uncertain. The NAVIGATE trial did not meet its primary composite endpoint in the ITT population.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.7 million cash balance plus the $10 million line of credit to fund operations through April 2027 and the terms of any potential new financing required thereafter.
- NAVIGATE Trial Path Forward: Confirm the outcome of the planned Type C meeting with the FDA and the specific design and funding requirements for any proposed Phase 3 trial.
- Related Party Financing: Review the terms of the convertible notes and lines of credit provided by Chairman Richard E. Uihlein, including conversion prices, interest rates, and the potential for significant dilution upon conversion.
- Derivative Liabilities: Assess the impact of the material weakness in internal controls on the valuation of derivative liabilities, which fluctuated significantly ($3.5 million loss in 2025) and affect net income.
- Intellectual Property: Review the expiration dates of key patents (many expiring between 2031 and 2034) and the status of the joint venture with Galectin Sciences LLC for oral inhibitor development.